Ondine Biomedical Inc.

AIM:OBI Stock Report

Market Cap: UK£57.2m

Ondine Biomedical Management

Management criteria checks 2/4

Ondine Biomedical's CEO is Carolyn Cross, appointed in Feb 2005, has a tenure of 21.08 years. total yearly compensation is CA$1.78M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 13.55% of the company’s shares, worth £7.74M. The average tenure of the management team and the board of directors is 3.7 years and 8 years respectively.

Key information

Carolyn Cross

Chief executive officer

CA$1.8m

Total compensation

CEO salary percentage29.75%
CEO tenure21.1yrs
CEO ownership13.5%
Management average tenure3.7yrs
Board average tenure8yrs

Recent management updates

Recent updates

User avatar

Mölnlycke Deal And US Trials Will Open International Markets

A major partnership is expected to enhance Steriwave's market entry and international sales, boosting revenue and growth opportunities significantly.

Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

Sep 28
Is Ondine Biomedical (LON:OBI) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Carolyn Cross's remuneration changed compared to Ondine Biomedical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-CA$24m

Mar 31 2025n/an/a

-CA$21m

Dec 31 2024CA$2mCA$529k

-CA$19m

Sep 30 2024n/an/a

-CA$17m

Jun 30 2024n/an/a

-CA$14m

Mar 31 2024n/an/a

-CA$14m

Dec 31 2023n/an/a

-CA$14m

Sep 30 2023n/an/a

-CA$17m

Jun 30 2023n/an/a

-CA$19m

Mar 31 2023n/an/a

-CA$19m

Dec 31 2022CA$892kCA$476k

-CA$19m

Sep 30 2022n/an/a

-CA$37m

Jun 30 2022n/an/a

-CA$54m

Mar 31 2022n/an/a

-CA$52m

Dec 31 2021CA$699kn/a

-CA$50m

Compensation vs Market: Carolyn's total compensation ($USD1.31M) is above average for companies of similar size in the UK market ($USD399.30K).

Compensation vs Earnings: Carolyn's compensation has increased whilst the company is unprofitable.

CEO

Carolyn Cross

21.1yrs
Tenure
CA$1,777,952
Compensation

Ms. Carolyn M. Cross, C.F.A. & M.B.A., has been Chairman and Chief Executive Officer of Sinuwave Technologies Corporation since 2011. She is founder of Ondine Biomedical Inc. and had been its Chairman sinc...

Leadership Team

NamePositionTenureCompensationOwnership
Carolyn Cross
Founder21.1yrsCA$1.78m13.55%
£ 7.7m
Nicolas Loebel
President21.9yrsCA$1.54m0.68%
£ 389.3k
Alan Thomas
Non-Board Interim CFOless than a yearno datano data
Angelika Vance
Vice President of Corporate Communications4.2yrsno datano data
Matt Ross
Vice President of Sales & Marketing3.2yrsno datano data
William Kanz
Senior VP of Engineering & Operationsno datano datano data
Elaine Lei
Corporate Controller & Company Secretary2yrsno datano data
Nikita Parkev
VP of Finance & Company Secretaryno datano datano data
3.7yrs
Average Tenure

Experienced Management: OBI's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Carolyn Cross
Founder22yrsCA$1.78m13.55%
£ 7.7m
Nicolas Loebel
President9.1yrsCA$1.54m0.68%
£ 389.3k
Jean Duvall
Senior Independent Non-Executive Director4.3yrsCA$133.29k0.22%
£ 128.0k
Richard Darveau
Member of Clinical Advisory Boardno datano datano data
Trisha O'Hehir
Member of Clinical Advisory Boardno datano datano data
Timothy Rose
Chairman of Clinical Advisory Boardno datano datano data
Sharon Compton
Member of Clinical Advisory Boardno datano datano data
Greg Chadwick
Member of Clinical Advisory Boardno datano datano data
Thomas Garthwaite
Chairman of Medical Advisory Board8yrsno datano data
Margaret Shaw
Independent Non-Executive Director1.5yrsCA$30.29k0.041%
£ 23.5k
Jean Charest
Independent Chairman of the Board8.2yrsCA$10.75k0.068%
£ 38.9k
Junaid Bajwa
Independent Non-Executive Director4.3yrsCA$122.54k0.23%
£ 131.3k
8.0yrs
Average Tenure
65.5yo
Average Age

Experienced Board: OBI's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/11 10:02
End of Day Share Price 2026/03/11 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ondine Biomedical Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David DeanATB Cormark Historical (Cormark Securities)
Charles WestonRBC Capital Markets
Jack Reynolds-ClarkRBC Capital Markets